Driehaus Capital Management’s Treace Medical Concepts TMCI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-188,915
Closed -$1.27M 485
2025
Q3
$1.27M Hold
188,915
0.01% 365
2025
Q2
$1.11M Sell
188,915
-279,363
-60% -$1.82M 0.01% 351
2025
Q1
$3.93M Buy
+468,278
New +$4.21M 0.04% 307
2023
Q4
Sell
-570,582
Closed -$7.48M 463
2023
Q3
$7.48M Sell
570,582
-906,534
-61% -$16.6M 0.1% 245
2023
Q2
$37.8M Buy
1,477,116
+724,926
+96% +$18.7M 0.48% 59
2023
Q1
$18.9M Sell
752,190
-18,627
-2% -$437K 0.27% 125
2022
Q4
$17.7M Buy
770,817
+62,141
+9% +$1.43M 0.26% 132
2022
Q3
$15.6M Buy
708,676
+259,735
+58% +$5.02M 0.24% 130
2022
Q2
$6.44M Sell
448,941
-2,894
-0.6% -$48.8K 0.1% 249
2022
Q1
$8.54M Buy
451,835
+154,321
+52% +$3M 0.1% 252
2021
Q4
$5.55M Sell
297,514
-14,690
-5% -$303K 0.06% 289
2021
Q3
$8.4M Sell
312,204
-2,369
-0.8% -$65.2K 0.1% 257
2021
Q2
$9.83M Buy
+314,573
New +$10M 0.13% 229

Other funds holding TMCI

Driehaus Capital Management's TMCI Position: Q4 2025 in Review

Driehaus Capital Management sold out of Treace Medical Concepts (TMCI) in Q4 2025, closing a stake of 188,915 shares — an estimated $1.27M sold.

Driehaus Capital Management first reported a position in TMCI in Q2 2021 and held it in 13 quarters. The position peaked at $37.8M in Q2 2023. 115 funds tracked by Wall St. Rank hold TMCI as of Q4 2025.

  • Driehaus Capital Management reported no remaining Treace Medical Concepts position as of Q4 2025 after selling out during the quarter.
  • Driehaus Capital Management sold 188,915 Treace Medical Concepts shares in Q4 2025, an estimated $1.27M.
  • Driehaus Capital Management first reported a position in Treace Medical Concepts in Q2 2021 and held it in 13 quarters.
  • Driehaus Capital Management's Treace Medical Concepts position peaked at $37.8M in Q2 2023.
  • 115 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q4 2025.

Based on Driehaus Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.